Edition:
United States

Armata Pharmaceuticals Inc (ARMP.A)

ARMP.A on American Stock Exchange

3.10USD
14 Jun 2019
Change (% chg)

$0.05 (+1.64%)
Prev Close
$3.05
Open
$3.15
Day's High
$3.15
Day's Low
$3.04
Volume
6,245
Avg. Vol
9,427
52-wk High
$19.18
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Ampliphi Biosciences Corp Reports Q4 Loss Per Share Of $0.15
Monday, 25 Mar 2019 09:01am EDT 

March 25 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AMPLIPHI BIOSCIENCES CORP QTRLY LOSS PER SHARE $0.15.AMPLIPHI BIOSCIENCES CORP - CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2018 TOTALED $8.2 MILLION.  Full Article

Ampliphi Biosciences And C3j Therapeutics Agree To Merge
Friday, 4 Jan 2019 08:00am EST 

Jan 4 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES AND C3J THERAPEUTICS AGREE TO MERGE.AMPLIPHI BIOSCIENCES CORP - CERTAIN EXISTING C3J SHAREHOLDERS HAVE COMMITTED TO INVEST $10 MILLION IN COMBINED COMPANY.AMPLIPHI BIOSCIENCES CORP - $10 MILLION TO BE INVESTED BY EXISTING C3J SHAREHOLDERS UPON CLOSING.AMPLIPHI BIOSCIENCES - COMBINED COMPANY'S TOTAL CASH BALANCE FOLLOWING CLOSING OF MERGER, CONTEMPLATED FINANCING EXPECTED TO BE ABOUT $18 MILLION.AMPLIPHI BIOSCIENCES CORP - CURRENT C3J SECURITYHOLDERS WILL OWN APPROXIMATELY 70% OF COMBINED COMPANY.AMPLIPHI BIOSCIENCES CORP - EXCHANGE RATIO IN MERGER AGREEMENT BASED ON $28 MILLION VALUATION FOR C3J, $12 MILLION VALUATION FOR AMPLIPHI.  Full Article

Ampliphi Biosciences Corp Qtrly Net Loss Per Share $0.10
Thursday, 8 Nov 2018 04:10pm EST 

Nov 8 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AMPLIPHI BIOSCIENCES CORP - CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2018 TOTALED $4.5 MILLION.AMPLIPHI BIOSCIENCES CORP - QTRLY NET LOSS PER SHARE, DILUTED $0.10.  Full Article

Ampliphi Biosciences Announces Pricing Of $6.6 Mln Underwritten Public Offering
Friday, 12 Oct 2018 06:00am EDT 

Oct 12 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES ANNOUNCES PRICING OF $6.6 MILLION UNDERWRITTEN PUBLIC OFFERING.AMPLIPHI BIOSCIENCES CORP - COMMON WARRANTS WILL BE IMMEDIATELY EXERCISABLE AT A PRICE OF $0.40 PER SHARE OF COMMON STOCK.AMPLIPHI BIOSCIENCES CORP - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 16.5 MILLION SHARES OF ITS COMMON STOCK AND COMMON WARRANTS.  Full Article

Ampliphi Biosciences Announces Registered Direct Offering Of Common Stock
Tuesday, 20 Mar 2018 08:00am EDT 

March 20 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES ANNOUNCES REGISTERED DIRECT OFFERING OF COMMON STOCK.AMPLIPHI BIOSCIENCES ANNOUNCES REGISTERED DIRECT OFFERING OF COMMON STOCK.AMPLIPHI BIOSCIENCES CORP - OFFERING 2.7 MILLION SHARES OF ITS STOCK AT A PRICE OF $1.10 PER SHARE​.  Full Article

Ampliphi Biosciences Reports Qtrly Loss Earnings Per Share $ 0.25
Wednesday, 14 Mar 2018 04:10pm EDT 

March 14 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AMPLIPHI BIOSCIENCES CORP - QTRLY LOSS EARNINGS PER SHARE $ 0.25.  Full Article

Ampliphi Biosciences Announces Pricing Of $4 Mln Public Offering Of Common Stock
Wednesday, 10 Jan 2018 06:00am EST 

Jan 10 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES CORP - ANNOUNCED PRICING OF PUBLIC OFFERING OF 4 MILLION COMMON SHARES AT $1.00 PER SHARE.AMPLIPHI BIOSCIENCES ANNOUNCES PRICING OF $4.0 MILLION PUBLIC OFFERING OF COMMON STOCK.  Full Article

Ampliphi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program For AB-SA01 And AB-PA01
Wednesday, 3 Jan 2018 04:05pm EST 

Jan 3 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES ANNOUNCES POSITIVE INTERIM RESULTS FOR SINGLE-PATIENT EXPANDED ACCESS PROGRAM UTILIZING AB-SA01 AND AB-PA01.AMPLIPHI BIOSCIENCES CORP - TREATMENT WAS WELL TOLERATED IN ALL PATIENTS, WITH OVER 500 DOSES ADMINISTERED INTRAVENOUSLY OR BY INHALATION.AMPLIPHI BIOSCIENCES CORP - SEVEN PATIENTS WITH SERIOUS INFECTIONS WERE TREATED WITH AB-SA01 OR AB-PA01, WITH 6 PATIENTS ACHIEVING TREATMENT SUCCESS.AMPLIPHI BIOSCIENCES CORP - EXPECTS TO CONTINUE ITS EXPANDED ACCESS CLINICAL STRATEGY IN 2018, REVIEW DATA WITH FDA IN MID-2018.AMPLIPHI BIOSCIENCES CORP - EXPECTS TO CONTINUE TO INITIATE A PHASE 2 OR REGISTRATIONAL CLINICAL PROGRAM POTENTIALLY AS EARLY AS SECOND HALF OF 2018.  Full Article

Ampliphi Biosciences Files For Offering Of Up To $10.0 Mln Of Common Stock
Thursday, 14 Dec 2017 05:11pm EST 

Dec 14 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES CORP FILES FOR OFFERING OF UP TO $10.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

AmpliPhi Biosciences Says Engaged Ladenburg Thalmann & Co To Review Strategic Alternatives
Thursday, 14 Dec 2017 04:10pm EST 

Dec 14 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES PROVIDES CORPORATE AND STRATEGIC UPDATE.AMPLIPHI BIOSCIENCES - ENGAGED LADENBURG THALMANN & CO. INC. TO REVIEW STRATEGIC ALTERNATIVES.  Full Article